Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Launched by BRISTOL-MYERS SQUIBB · Aug 1, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to learn more about how adults with schizophrenia in the United States feel about a new treatment called xanomeline and trospium chloride (XT) therapy. The study aims to understand patients’ preferences and satisfaction with this treatment to help improve care. It is not yet open for participants.

To take part, individuals need to be at least 18 years old, have a confirmed diagnosis of schizophrenia, and have just received their first prescription for the XT therapy with plans to start it. Participants should be able to speak English or Spanish and agree to share their experiences using an electronic device or paper forms. People who have recently been in other clinical trials or who have used this treatment before cannot join. If eligible, participants will be asked to report how they feel about the treatment over time, helping doctors understand its impact on daily life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged ≥18 years at index date.
• • Have a confirmed diagnosis of schizophrenia before index date.
• • Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy.
• • Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines.
• • Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish).
• • English or Spanish speaking.
• Exclusion Criteria:
• • Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening.
• • Evidence of use of XT prior to time of eligibility screening.